Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $11.1 million.

  • UroGen Pharma's Accumulated Expenses rose 23.09% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 23.09%. This contributed to the annual value of $10.6 million for FY2024, which is 2.26% down from last year.
  • Latest data reveals that UroGen Pharma reported Accumulated Expenses of $11.1 million as of Q3 2025, which was down 4.57% from $11.6 million recorded in Q2 2025.
  • UroGen Pharma's Accumulated Expenses' 5-year high stood at $11.6 million during Q2 2025, with a 5-year trough of $4.7 million in Q1 2021.
  • For the 3-year period, UroGen Pharma's Accumulated Expenses averaged around $8.3 million, with its median value being $8.2 million (2023).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first decreased by 27.28% in 2021, then spiked by 70.04% in 2025.
  • Over the past 5 years, UroGen Pharma's Accumulated Expenses (Quarterly) stood at $6.9 million in 2021, then increased by 18.84% to $8.3 million in 2022, then soared by 30.97% to $10.8 million in 2023, then dropped by 2.26% to $10.6 million in 2024, then climbed by 23.09% to $11.1 million in 2025.
  • Its Accumulated Expenses was $11.1 million in Q3 2025, compared to $11.6 million in Q2 2025 and $7.0 million in Q1 2025.